Multiple myeloma is an incurable cancer characterized by the uncontrolled growth of
malignant plasma cells nurtured within a permissive bone marrow microenvironment. While …

Avoiding immune destruction is a hallmark of cancer. Over the past few years, significant
advances have been made in understanding immune dysfunction and immunosuppression …

Dendritic cell-derived exosomes (Dex) are small extracellular vesicles secreted by viable
dendritic cells. In the two phase-I trials that we conducted using the first generation of Dex …

Therapeutic vaccines represent a viable option for active immunotherapy of cancers that aim
to treat late stage disease by using a patient's own immune system. The promising results …

Chimeric antigen-receptor (CAR) T cells lead to high response rates in myeloma, but most
patients experience recurrent disease. We combined several high-dimensional approaches …

BACKGROUND. Multiple myeloma is usually fatal due to serial relapses that become
progressively refractory to therapy. CD19 is typically absent on the dominant multiple …

We conducted a phase I clinical trial of anti-BCMA chimeric antigen receptor T cells (CART-
BCMA) with or without anti-CD19 CAR T cells (huCART19) in multiple myeloma (MM) …

Tumor immunity represents a new avenue for cancer therapy. Immune checkpoint inhibitors
have successfully improved outcomes in several tumor types. In addition, currently, immune …

Glioblastoma, the most aggressive cerebral tumor, is invariably lethal. Glioblastoma cells
express several genes typical of normal neural stem cells. One of them, SOX2, is a master …

Preneoplastic lesions carry many of the antigenic targets found in cancer cells but often
exhibit prolonged dormancy. Understanding how the host response to premalignancy is …